U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. OTP Events, Meetings, and Workshops
  4. FDA CBER Webinar: Human Gene Therapy Products Incorporating Human Genome Editing - 02/29/2024
  1. OTP Events, Meetings, and Workshops

Webcast | Virtual

Event Title
FDA CBER Webinar: Human Gene Therapy Products Incorporating Human Genome Editing
February 29, 2024

Date:
February 29, 2024
Time:
1:00 p.m. - 2:00 p.m. ET
Organized By:
Organizer

The FDA Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) hosted a virtual public webinar on Thursday, February 29 at 1:00 pm to discuss a recently finalized guidance document on developing human gene therapy products that incorporate human genome editing. This guidance is intended to assist industry members and provide them with recommendations on what to include in an investigational new drug (IND) application, and how best to design, manufacture, and test these products.

FDA CBER Genome Editing Webinar Banner, Thursday, February 29, 2024 1-2pm ET

 

In this webinar, CBER subject matter experts highlighted key considerations in the final guidance.

View the recording for the FDA CBER Webinar on Human Gene Therapy Products Incorporating Human Genome Editing.

About FDA CBER OTP

FDA CBER OTP oversees development for a wide variety of biological products, including gene and cell therapies, tissues and tissue engineering products, xenogeneic products, and more. OTP strives to lead all regulatory decisions with data, impartiality, and compassion and always welcomes the participation of patients and their advocates in formal meetings related to the development of investigational products. Learn more about OTP and view information on other meetings and workshops.

Stay Connected

Sign up for the CBER Listserv or follow us on social media to stay up to date on all FDA CBER news and events.

Back to Top